At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 76 enrolled
Drug / intervention
Carfilzomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies
In Brief
A Phase 2 clinical trial evaluating Carfilzomib, Cyclophosphamide, and 1 other intervention for Multiple Myeloma. Completed, enrolled 76 participants across 9 sites.
Detailed Summary
The purpose of this study is to find out what effects carfilzomib has on relapsed multiple myeloma when administered in combination with cyclophosphamide and dexamethasone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesCanada
CollaboratorsAmgen, Canadian Myeloma Research Group
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartJul 2016
Primary CompletionJun 2019
Study CompletionFeb 2022
TodayJul 2026
First PostedNov 4, 2015
Enrollment StartJul 5, 2016
Primary CompletionJun 19, 2019
Study CompletionFeb 1, 2022
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 10.7 years ago
Interventions
Carfilzomibdrug
Cyclophosphamidedrug
Dexamethasonedrug